Answers are grounded in this paper and cite their sources.
Demonstrates that melatonin improves lipid profiles and alters TNF-α in diabetic rats, suggesting a beneficial effect on diabetes-induced dyslipidemia.
In this study, it was aimed to determine the effects of melatonin application on lipid profile in streptozotocin-induced diabetic rats . Animals in control group were not any treatment. Melatonin group animals received 50 mg/kg melatonin intraperitoneally in daily for eight weeks. Diabetes was induced by subcutaneous injections of streptozotocin at dose of 40 mg/kg for two days as a single dose per day in diabetes group animals. Animals in Diabetes+Melatonin group were made diabetic by streptozotocin in the same way and then these animals received 50 mg/kg melatonin intraperitoneally in daily for eight weeks. In blood samples taken from all animals, TNF-α, triglyceride, total cholesterol, LDL and HDL were determined. In diabetes group, TNF-α level were high (p<0.05). The changes in TNF-α level with melatonin application to diabetic rats were important (p<0.05). In diabetic rats, triglyceride and LDL levels were found to be enhanced compared to control group (p<0.05), HDL level was significantly low (p<0.05), while the change in total cholesterol level was not important. With the melatonin application to diabetic rats, HDL level was found to be higher (p<0.05) and LDL level was lower than diabetes group (p<0.05). It was concluded that the administration of melatonin to streptozotocin-induced diabetic rats may have positive effects on lipid profile.
No takes yet. Share an insight, caveat, or question.
Uluışık et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: